Article
Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.
Clinical colorectal cancer - 1 Sept 2026
Samaille Thomas, Raeisi Morteza, Cohen Romain, Shi Qian, Yoshino Takayuki, Zalcberg John R, Adams Richard, Cremolini Chiara, Grothey Axel, Mayer Robert J, Chibaudel Benoist, de Gramont Aimery, André Thierry
Abstract excerpt
BACKGROUND: KRAS mutations in metastatic colorectal cancer (mCRC) are a factor of poor prognosis, partly because of associated resistance to anti-EGFR therapies. Liver metastases (LM) were also described as a factor of poor prognosis. This study aims to compare the outcomes of patients treated in third-line setting with placebo or Trifluridine/Tipiracil or regorafenib (TToR) and to assess the impact of LM and...
Read the complete abstract on PubMedTopics
- Humans
- Colorectal Neoplasms
- Liver Neoplasms
- Proto-Oncogene Proteins p21(ras)